This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Vrinten, D. H. Articles by Gispen, W. H. Search for Related Content PubMed PubMed Citation Articles by Vrinten, D. H. Articles by Gispen, W. H. Related Collections Mechanisms Pain

---

PAIN MEDICINE

Chronic Blockade of Melanocortin Receptors Alleviates Allodynia in Rats with Neuropathic Pain

Dorien H. Vrinten, MD^*, Roger A. H. Adan, PhD^*, Gerbrand J. Groen, MD, and Willem Hendrik Gispen, PhD^*

Departments of *Medical Pharmacology and Anesthesiology, Rudolf Magnus Institute for Neurosciences, University Medical Centre Utrecht, Utrecht, the Netherlands

Address correspondence and reprint requests to Dr. W. H. Gispen, Department of Medical Pharmacology, Rudolf Magnus Institute for Neurosciences, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, the Netherlands. Address e-mail to w.h.gispen{at}med.uu.nl

We investigated the involvement of the spinal cord melanocortin (MC) system in neuropathic pain. Because we recently demonstrated that MC receptor ligands acutely alter nociception in an animal model of neuropathic pain, in this study we tested whether chronic administration was also effective. We hypothesized that chronic blockade of the spinal MC system might decrease sensory abnormalities associated with this condition. The effects of the MC receptor antagonist SHU9119 (0.5 µg/d) and agonist MTII (0.1 µg/d) were evaluated in rats with a chronic constriction injury of the sciatic nerve. Drugs were continuously infused into the cisterna magna. Antinociceptive effects were measured with tests involving temperature (10°C or 47.5°C) or mechanical (von Frey) stimulation. The administration of MTII increased mechanical allodynia, whereas SHU9119 produced a profound cold and mechanical antiallodynia, altering responses to control levels. The antiallodynic effects of SHU9119 were very similar to those produced by the ₂-adrenergic agonist tizanidine (50 µg/d). The effects of SHU9119 and MTII are most likely mediated through the MC4 receptor, because this is the only MC-receptor subtype present in the spinal cord. We conclude that the chronic administration of MC4-receptor antagonists might provide a promising tool in the treatment of neuropathic pain.

IMPLICATIONS: In this study we demonstrated that continuous intrathecal infusion of the melanocortin-receptor antagonist SHU9119 reduces cold and mechanical allodynia in rats with a chronic constriction injury of the sciatic nerve, a lesion producing neuropathic pain.

This article has been cited by other articles:

				S. Chaki, S. Hirota, T. Funakoshi, Y. Suzuki, S. Suetake, T. Okubo, T. Ishii, A. Nakazato, and S. Okuyama Anxiolytic-Like and Antidepressant-Like Activities of MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 818 - 826. [Abstract] [Full Text] [PDF]

				Y. Yang, M. Chen, Y. Lai, I. Gantz, K. E. Georgeson, and C. M. Harmon Molecular Determinants of Human Melanocortin-4 Receptor Responsible for Antagonist SHU9119 Selective Activity J. Biol. Chem., May 31, 2002; 277(23): 20328 - 20335. [Abstract] [Full Text] [PDF]